Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

  • End date
    Dec 31, 2025
  • participants needed
  • sponsor
    M.D. Anderson Cancer Center
Updated on 15 February 2022
ct scan
platelet count
stem cell transplantation
measurable disease
neutrophil count
refractory mantle cell lymphoma


This phase II trial studies how well ultra low dose radiation works before or after chemotherapy-free targeted therapy in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Ultra low dose radiation is generally associated with a lower risk of side effects which may allow patients to be able to receive low-dose radiation therapy more often than high-dose radiation therapy. This trial may help doctors learn if giving ultra low dose radiation helps control mantle cell lymphoma and improves response to chemotherapy free targeted therapy.



I. To evaluate the efficacy of adding ultra low dose radiation (ULDR) to chemotherapy free-targeted therapy (CTFTT) in contributing to a durable overall response in treated locations by estimating overall response rate (ORR) at 3 months.


I. To evaluate if ULDR can improve progression-free survival and overall survival.

II. To evaluate the prognostic factors associated with inferior progression-free survival, including patient related and previous treatment related and if radiation can overcome these prognostic factors.

III. To evaluate if radiation helps to bridge patients to other investigational drugs, by decreasing the disease bulk, controlling their symptoms, and maintaining a good performance status.


Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.

Condition Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Treatment Low Dose Radiation Therapy
Clinical Study IdentifierNCT04054167
SponsorM.D. Anderson Cancer Center
Last Modified on15 February 2022


Yes No Not Sure

Inclusion Criteria

Patients must have a confirmed diagnosis of mantle cell lymphoma with positivity in tissue biopsy. Biopsy does not need to be done of the lesions to be treated
Patients must have previously treated relapsed and/or refractory mantle cell lymphoma (MCL) with at least 2 prior lines of therapy (prior carfilzomib, ibrutinib, bortezomib, anthracycline, rituximab or stem cell transplant are acceptable). There is no upper limit for prior lines of therapy
Patients must have demonstrated progressive disease on positron emission tomography (PET)/computed tomography (CT) imaging following ibrutinib treatment, mono- or combinatorial therapy, in the relapsed/refractory setting
Understand and voluntarily sign an Institutional Review Board (IRB)-approved informed consent form
Patients must have bi-dimensional measurable disease (measurable disease by CT scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension.) Patient presenting with lesions in the as at least 1 lesion that measures >= 1.5 cm in single dimension.) Patient presenting with lesions in the presence of leukemia phase (peripheral blood involvement), non-measurable disease, gastrointestinal (GI) MCL, or bone marrow (BM) MCL are also eligible
Gastrointestinal or bone marrow or spleen only patients are allowable and will be analyzed separately
Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test and must be willing to use acceptable methods of birth control during the study and for 30 days after the last dose of study treatment
Male patients must use an effective barrier method of contraception during the study and for 30 days following the last dose of study treatment if sexually active with a female of childbearing potential
Serum bilirubin less than 1.5 mg/dl
Creatinine (Cr) clearance greater than or equal to 30 mL/min
Platelet count greater than 25,000/mm^3
Absolute neutrophil count (ANC) greater than 1,000/mm^3
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) less than 3 x upper limit of normal or less than 5 x upper limit of normal if hepatic metastases are present
Patients who have bone marrow infiltration by MCL are eligible if their ANC is greater than or equal to 1000/mm^3 (growth factor not allowed) or their platelet level is greater than or equal to 25,000/mm^3

Exclusion Criteria

Has had prior radiation therapy to the potential radiation target such that additional radiation therapy is considered unsafe by the treating radiation oncologist
Has a diagnosis of active scleroderma or lupus or any other autoimmune disease that by the opinion of the treating radiation oncologist would put the patient at unacceptable risk of toxicity
Any serious medical condition including but not limited to, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled infection, active/symptomatic coronary artery disease, chronic obstructive pulmonary disease (COPD), renal failure, active hemorrhage, or psychiatric illness that, in the investigators opinion places the patient at unacceptable risk and would prevent the subject from signing the informed consent form
Pregnant or breast-feeding females
All patients with central nervous system lymphoma that needs attention prior to treatment of the lesions
If the total fields of radiation will include a marrow volume of more than 40%. Physician can include as many fields to respect the 40% of marrow volume and come back in 4-6 weeks later to address the rest of the disease after insuring that the blood counts are adequate. Blood counts should be back to back to the numbers prior to starting the first phase of radiation + or - 10% variance
If giving radiation prevents them from going through an alternative phase I trial that could be beneficial like chimeric antigen receptor (car) T cell treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note